KB Home Q3 Results Beat Estimates, Cut Margin Outlook

KB Home Q3 results beat revenue and EPS while management trimmed full-year gross-margin guidance, a development likely to pressure shares.

September 22, 2026·2 min read
View all news articles
Flat vector model home with dimming porch light symbolizing KB Home Q3 results and trimmed margin guidance tradeoff.

KEY TAKEAWAYS

  • Reported $1.3 billion revenue and $1.05 diluted EPS for the quarter.
  • Lowered full-year housing gross-profit margin guidance to 16.0%-16.2%.
  • Repurchased about $50 million in the quarter and $175 million year to date.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

KB Home’s Q3 results on Sept. 22, 2026 showed the company beat consensus on revenue and earnings while trimming its full-year housing gross-profit margin outlook amid weakening housing conditions and ongoing share repurchases.

Results and Outlook

The company reported third-quarter revenue of $1.30 billion and diluted earnings per share of $1.05 for the period ended Aug. 31, 2026. These figures exceeded consensus estimates of about $0.88–$0.89 per share and roughly $1.29 billion in revenue. KB Home repurchased approximately 0.9 million shares for $50 million during the quarter and about 3.1 million shares for $175 million year to date.

KB Home lowered its full-year housing gross-profit margin guidance to 16.0%–16.2% from 16.1%–16.5% but maintained delivery and revenue targets of 10,500–11,000 homes and $4.9 billion–$5.1 billion.

Operations and Capital Allocation

Net income fell to $65 million from $110 million a year earlier, while homebuilding operating income declined to $67 million from $131 million. Deliveries dropped to 2,732 homes from 3,393, and net orders fell 12% to 2,604 homes. Net-order value declined about 8% to roughly $1.21 billion.

Housing gross profit margin on a reported basis decreased to 16.5% from 18.2% a year earlier. Adjusted margin was 16.8%, down from 18.9%. Management attributed margin pressure to mortgage-rate increases, affordability challenges, higher resale inventory, and cautious consumer demand.

The backlog rose modestly to 4,398 homes valued at about $2.05 billion, up roughly 2% in units and 3% in value from the prior year.

The quarter highlighted a familiar tradeoff for investors: results that beat expectations were tempered by lowered margin guidance and signs of softer volumes, even as KB Home continued returning capital through share repurchases.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Binance Invests in Circle With $100 Million Stake

Binance Invests in Circle With $100 Million Stake

Binance invests in Circle with $100 million and an expanded USDC partnership; the filing lists a lockup and incentive fee that may pressure CRCL stock.

Meta Muse Downloads Spur CapEx Debate

Meta Muse Downloads Spur CapEx Debate

Meta Muse downloads topped app charts, prompting investor debate over whether adoption will convert to subscriptions and alter Meta's capital plans.

Meta Muse Shopify Integration Raises Stakes for Payments

Meta Muse Shopify Integration Raises Stakes for Payments

Reports linking Meta Muse Shopify integration to Shop Pay refocused traders on checkout and payments prospects after Meta's Sept. 16 Meta One announcement.

SanDisk Stock Draws Rosenblatt Buy on AI Demand

SanDisk Stock Draws Rosenblatt Buy on AI Demand

SanDisk stock drew Rosenblatt coverage on Sept. 22, 2026, citing AI storage demand and eight customer deals that tighten demand visibility and positioning.

AutoZone Earnings Beat; Revenue Mixed

AutoZone Earnings Beat; Revenue Mixed

AutoZone earnings showed an EPS beat driven by tariff refunds and a net noncash LIFO benefit, a mixed release that could prompt trading reweights.

Viking Therapeutics VK2735 Results

Viking Therapeutics VK2735 Results

Viking Therapeutics VK2735 results show robust weight loss and durable maintenance on less-frequent dosing, prompting investor reappraisal.